Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.
Press releases published on August 12, 2025
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
GlobeNewswire
·
August 12, 2025
MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has …
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 12, 2025
Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation …
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 12, 2025
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in …
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
August 12, 2025
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available during 4Q …
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 12, 2025
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent …
Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands
GlobeNewswire
·
August 12, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane’s and …
SRx Health Solutions Initiates Restructuring Proceedings under CCAA for its Canadian Subsidiary
GlobeNewswire
·
August 12, 2025
TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that its subsidiary, SRx Health Solutions (Canada), Inc. (“SRx Canada”) and …
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewswire
·
August 12, 2025
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H …
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
GlobeNewswire
·
August 12, 2025
BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a …
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 12, 2025
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New …
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
GlobeNewswire
·
August 12, 2025
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the …
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 12, 2025
Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4% …
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
GlobeNewswire
·
August 12, 2025
$20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company’s financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. …
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
GlobeNewswire
·
August 12, 2025
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company …
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
GlobeNewswire
·
August 12, 2025
Funding combines equity investment and convertible loan Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs Dr. Thomas Hecht has joined Board …
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 12, 2025
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, …
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
GlobeNewswire
·
August 12, 2025
VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through artificial …
Phonak unveils Virto R Infinio: the compact rechargeable hearing aid designed for today's active lifestyle
GlobeNewswire
·
August 12, 2025
STÄFA, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in hearing care solutions is excited to introduce the Virto R Infinio, its most compact rechargeable custom in-the-ear (ITE) hearing aid powered by the advanced Infinio …
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
GlobeNewswire
·
August 12, 2025
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support global Sandoz decarbonization efforts and sustainability …
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 12, 2025
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 financial outlook confirmed Saint-Herblain (France), August 12 …